legal-news
1:19-md-02875 VALSARTAN LOSARTAN AND IRBESARTAN PRODUCTS LIABILITY LITIGATION
19-md-02875
|
|
Filed
Active
Sign in to follow this case
Advertisement
description
Case Summary
The case titled 1:19-md-02875 VALSARTAN LOSARTAN AND IRBESARTAN PRODUCTS LIABILITY LITIGATION involves multidistrict litigation concerning alleged product liability claims related to the blood pressure medications valsartan, losartan, and irbesartan. Plaintiffs in this litigation assert that these medications were contaminated with potentially carcinogenic substances, leading to health risks and damages. The litigation consolidates numerous individual cases to streamline pretrial proceedings and manage complex discovery and motions efficiently. The court's orders in this matter typically address procedural and substantive issues arising from the coordination of these claims across multiple jurisdictions.
Key Issues
- • Product liability and pharmaceutical contamination
- • Multidistrict litigation procedures
- • Causation and damages related to contaminated medications
- • Regulatory compliance and FDA oversight
- • Class certification and case management
Advertisement
Case Timeline
1 event
gavel
Order
April 14, 2026
1:19-md-02875 VALSARTAN LOSARTAN AND IRBESARTAN PRODUCTS LIABILITY LITIGATION
[Order]
Advertisement
newspaper
1 article